Rieckmann K, Davis D, Hutton D. Plasmodium vivax resistance to chloroquine? [J]. The Lancet, 1989,334(8673): 1183-1184.
[2]
WHO. World malaria report 2011[R]. Geneva 2011.
[3]
Guerra CA, Howes RE, Patil AP, et al. The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009 [J]. PLoS Negl Trop Dis, 2010,4(8): 774.
[4]
Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis [J]. The Lancet, 2012,379(9814): 413-431.
[5]
WHO. Factsheet on the World Malaria Report 2012.2012
[6]
Rogerson SJ, Carter R. Severe vivax malaria: Newly recognised or rediscovered? [J]. Plos Med, 2008,5(6): 136-141.
[7]
Anstey NM, Russell B, Yeo TW, et al. The pathophysiology of vivax malaria [J]. Trends in parasitology, 2009,25(5): 220-227.
[8]
Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy [J]. Clinical Infectious Dis, 2009,48(12): 1704-1712.
[9]
John GK, Douglas NM, Von SL, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature [J]. Malar J, 2012,11: 280-290.
[10]
Krudsood S, Tangpukdee N, Wilairatana P, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria [J]. The American J of Tropical Med and Hygiene, 2008,78(5): 736-740.
[11]
Durand S, Cabezas C, Lescano AG, et al. Efficacy of Three Different Regimens of Primaquine for the Prevention of Relapses of Plasmodium vivax Malaria in the Amazon Basin of Peru [J]. The American Journal of Tropical Medicine and Hygiene, 2014: 13-53.
[12]
Ministry of Health, People’s Republic of China: Malaria elimination action plan 2010-2020 [R]. Beijing: 2009:1-2.
[13]
Ministry of Health, People’s Republic of China: From malaria control to elimination: a revised national malaria strategy 2010-2015 [R].Beijing:2009:2-4.
[14]
Cotter C, Sturrock HJ, Hsiang MS, et al. The changing epidemiology of malaria elimination: new strategies for new challenges [J]. The Lancet, 2013,382(9895): 900-911.
[15]
Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial [J]. Clinical Infectious Dis, 2011,53(10): 977-984.
[16]
Khattak AA, Venkatesan M, Khatoon L, et al. Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan [J]. Malar J, 2013,12(1): 310-318.
[17]
Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia[J]. New England J of Med, 2009,361(5): 540-541.
[18]
Group QACR. Antimalaria studies on qinghaosu [J]. Chin med J, 1979,92(12): 811-816.
[19]
Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria [J]. The Lancet infectious diseases, 2010,10(6): 405-416.
[20]
Gama BE, Lacerda MVG, Daniel RCT, et al. Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: consequences on disease morbidity and control [J]. Memorias do Instituto Oswaldo Cruz, 2011,106: 159-166.
[21]
Liu H, Yang Hl, Xu JW, et al. Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China[J]. Malar J, 2013,12(1): 409-416.
[22]
Santelli AC, Ribeiro I, Daher A, et al. Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in amazon basin communities [J]. Malar J, 2012,11: 286-297.
[23]
Pasaribu AP, Chokejindachai W, Sirivichayakul C, et al. A Randomized Comparison of Dihydroartemisinin-Piperaquine and Artesunate-Amodiaquine Combined With Primaquine for Radical Treatment of Vivax Malaria in Sumatera, Indonesia [J]. J of Infectious Dis, 2013,208(11): 1906-1913.
[24]
Nithya G, Sridharan A, Mau TU, et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria[J]. Cochrane Database Syst Rev, 2013,10:1-9.
[25]
Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial [J]. Plos One, 2009,4(11): 7871.
[26]
Calleri G, Castelli F, Hamad I, et al. New Italian guidelines for malaria prophylaxis in travellers to endemic areas [J]. Infection, 2014,42(1): 239-250.
[27]
Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy [J]. Clinical Infectious Dis, 2013,56(3): 383-397.
[28]
White NJ, Pukrittayakamee S, Hien TT, et al. Malaria [J]. The Lancet, 2014,383(9918): 723-735.
